Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageANI Pharmaceuticals is a diversified bio-pharmaceutical company. The Company's mission is “Serving Patients, Improving Lives” by developing, manufacturing, and commercializing therapeutics through its Rare Disease, Generics, and Brands businesses. On September 16, 2024, the Company acquired Alimera Sciences, Inc. ("Alimera"). In connection with the acquisition, the Company added two new products, ILUVIEN® ("ILUVIEN") and YUTIQ® ("YUTIQ").
In the company’s own words · 10-K filed Feb 27, 2026 · SEC EDGAR
Business segments
Jun 2026 · $255.3MThe company’s own SEC segment disclosure.
- Total Sales Of Generics And Other$100.7M39%
- Sales Of Generic Pharmaceutical Products$99.1M39%
- Sales Of ILUVIEN And YUTIQ$18.7M7%
- Sales Of Established Brand Royalties And Other$17.7M7%
- Sales Of Established Brands$11.8M5%
- Unapproved Products$5.7M2%
- Other (1)$1.6M1%
ANI Pharmaceuticals, Inc. (ANIP) reported revenue of $237M in Q1 2026 (quarter ended Mar 31, 2026), up 20% from the same quarter a year earlier. That came with a gross margin of 61% and net income of $29M (12% of revenue). For the full year FY2025, revenue was $883M (+44% year on year) and net income $78M. Its largest product in Jun 2026 was Total Sales Of Generics And Other at $101M, 39.4% of the disclosed total, just ahead of Sales Of Generic Pharmaceutical Products at 38.8%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Drug Manufacturers - Specialty & Generic
Ranks #13 of 29 by Smart Score